Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?

Authors


Correspondance

Mitchell L Shiffman, MD, Liver Institute of Virginia, 5855 Bremo Road, Suite 509, Richmond, VA 23226, USA

Tel: +804 877 8920

Fax: +757 947 3195

e-mail: Mitchell_shiffman@bshsi.org

Abstract

The current standard of care (SOC) for patients with chronic HCV genotype 1 is a combination of either boceprevir or telaprevir with peginterferon (PEG-IFN) and ribavirin (RBV). Although it is effective in a high percentage of patients, this treatment is associated with significant adverse events (AEs). The next generation of protease inhibitors, simeprevir and faldaprevir, will also be used with PEG-IFN/RBV. Interferon-free therapy with sofosbuvir appears promising and on the horizon for patients with genotypes 2 and 3, but may still be many years away for patients with HCV genotype 1. The factors which should be considered when deciding whether to treat a patient with HCV and mild fibrosis with the current SOC now, or to delay treatment until less toxic and/or more effective therapy is available is discussed.

Ancillary